Loading...
Horizon Therapeutics Public Limited Company
HZNP•NASDAQ
Healthcare
Drug Manufacturers - General
$116.30
$0.00(0.00%)
Horizon Therapeutics Public Limited Company (HZNP) AI-Powered Stock Analysis
See how Horizon Therapeutics Public Limited Company scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerHorizon Therapeutics Public Limited Company (HZNP) Stock Overall Grade
Horizon Therapeutics Public Limited Company’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B+
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Horizon Therapeutics Public Limited Company's overall stock rating.
Forecast
A+Score
100/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
B+Score
70/100Sector Comparison
B+Score
75/100Industry Comparison
A+Score
90/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Horizon Therapeutics Public Limited Company (HZNP) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 100/100 (A+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (70/100, B+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Horizon Therapeutics Public Limited Company stock grade, including financials, comparisons, and forecasts.